Clinical and Translational

LeukoVantage: A Quest/Qiagen Partnership Providing Clinical Insights Into Myeloid Malignancies

December 09, 2019

The integration of next-generation sequencing (NGS) into the diagnostic process for hematologic malignancies has greatly improved the accuracy and speed of confirming or refining the diagnosis and following minimal residual disease. Optimization of gene selection and assay development, together with skilled interpretation, are key factors in the execution of a clinically relevant NGS test for hematologic malignancies.

In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation. LeukoVantage covers the most important genes for myeloid diagnostics, with focused panels that allow rapid turnaround. N-of-One’s team of experienced PhDs provides expert, evidence-based annotation incorporating WHO, NCCN, and ELN guidelines, with clinically relevant information vetted by oncologists. N-of-One reports include diagnostic and prognostic information, therapeutic options, and clinical trials based on the unique combination of genomic alterations detected in each case. These reports are then reviewed, modified, and signed out by Quest pathologists.

Interested in learning more?

Click here


Sheryl Krevsky Elkin, PhD, Chief Scientific Officer, N-of-One, a QIAGEN company

Frederick K. Racke, MD, PhD, Medical Director Hematology/Oncology and Coagulation, Nichols Institute San Juan Capistrano, CA

Related videos

Clinical and Translational

How to reduce your test turnaround for large panels in molecular oncology

263 views December 31, 2019

Speaker: Sheryl Elkin, CSO, N-of-One.a QIAGEN Company Interested in learning...

Clinical and Translational

Cancer Gene Variant Detection Using a Pre-Optimized Sample to Report Workflow

271 views October 30, 2019

BRCA1/BRCA2 genes represent the best examples for our current understanding...

Clinical and Translational

Increasing the efficiency of diagnostic odysseys

323 views September 16, 2019

Despite rapid cost reductions in sequencing technologies and an...

Clinical and Translational

Managing Multiple Biomarker Therapeutic Development

310 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...